Product Description
EVX-020, Sole-in-class KIF20A inhibitor - Next generation ADC payload. A selective KIF20A inhibitor to tackle highly proliferative cancers. By combining the great efficacy and broad therapeutic scope of chemotherapy and the safety potential of targeted therapy, the KIF20A inhibitor EVX-020 (formerly DIACC2010) brings chemotherapy in the era of precision medicine. Non-clinical efficacy was established in acute myeloid leukemia models. (Sourced from: https://www.evextabio.com/rd-programs/evx-020-sole-class-kif20a-inhibitor-next-generation-adc-payload)
Mechanisms of Action: KIF20A Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Evexta
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Acute Myeloid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|